Article citationsMore>>
Huang, L., Shah, K., Barat, B., Lam, C.-Y.K., Gorlatov, S., Ciccarone, V., Tamura, J., Moore, P.A. and Diedrich, G. (2020) Multispecific, Multivalent Antibody-Based Molecules Engineered on the DART® and TRIDENTTM Platforms. Current Protocols in Immunology, 129, e95.
https://doi.org/10.1002/cpim.95
has been cited by the following article:
-
TITLE:
Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy
AUTHORS:
Zhenqi Xu, Can Gao, Mengru Jian, Wei Du
KEYWORDS:
Genetically Engineered, Multi-Specific Antibody, Tumor Therapy
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.3,
March
24,
2023
ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.